Showing results (61-70 of 77) with videos related to
Sort By:
Pageof 8
Bioorganic & Medicinal Chemistry Letters|January 18, 2014
Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Peter S Dragovich, Guiling Zhao, Timm Baumeister, et al.Open Forum Infectious Diseases|October 29, 2020
Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center ExperienceMarkos Kalligeros, Karen T Tashima, Evangelia K Mylona, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast CancerIan Krop, Vandana Abramson, Marco Colleoni, et al.Journal of Medicinal Chemistry|December 5, 2014
Discovery of 2-(cyclohexylmethylamino)pyrimidines as a new class of reversible valosine containing protein inhibitorsGiovanni Cervi, Paola Magnaghi, Daniela Asa, et al.ACS Medicinal Chemistry Letters|December 30, 2015
Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar MoietyChudi O Ndubaku, James J Crawford, Joy Drobnick, et al.Journal of Medicinal Chemistry|July 18, 2013
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitorsXiaozhang Zheng, Paul Bauer, Timm Baumeister, et al.Journal of Medicinal Chemistry|January 11, 2014
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Anthony M Giannetti, Xiaozhang Zheng, Nicholas J Skelton, et al.Bioorganic & Medicinal Chemistry Letters|January 22, 2022
Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenaseBinQing Wei, Kirk Robarge, Sharada S Labadie, et al.Journal of Medicinal Chemistry|May 12, 2016
Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic WindowJoachim Rudolph, Lesley J Murray, Chudi O Ndubaku, et al.Bioorganic & Medicinal Chemistry Letters|January 4, 2015
Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubilityMark Zak, Bianca M Liederer, Deepak Sampath, et al.Pageof 8